Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR139 | Q6DWJ6 | 9/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | GLA | P06280 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | ATM | Q13315 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | STAT1 | P42224 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5152700 | 0.84 | TP53 (0.38) | KDM4EGLAALDH1A1HPGDMAPT | |
| SCHEMBL5152476 | 0.82 | POLB (0.38) | KDM4EGLAALDH1A1HPGDKMT2A | |
| SCHEMBL5388545 | 0.74 | LMNA (0.39) | KDM4EGLAALDH1A1HPGDKMT2A | |
| SCHEMBL6133369 | 0.74 | LMNA (0.39) | KDM4EGLAALDH1A1HPGDKMT2A | |
| SCHEMBL5150644 | 0.74 | POLB (0.40) | KDM4EGLAALDH1A1HPGDATM | |
| SCHEMBL5152518 | 0.72 | LMNA (0.34) | ALDH1A1HPGDKMT2AMAPT | |
| SCHEMBL6923211 | 0.71 | ALDH1A1 (0.38) | KDM4EGLAALDH1A1HPGDMEN1 | |
| SCHEMBL6539221 | 0.69 | ALDH1A1 (0.46) | KDM4EGLAALDH1A1HPGDMEN1 | |
| SCHEMBL27679545 | 0.66 | ALDH1A1 (0.46) | KDM4EGLAALDH1A1HPGDMEN1 | |
| SCHEMBL5147931 | 0.65 | POLB (0.44) | KDM4EGLAALDH1A1HPGDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7265120-B2 | Pyrazine derivatives and pharmaceutical use thereof | ASTELLAS PHARMA INC. (JP) | 2007-09-04 | — | — | US | disclosed |
| US-20050222159-A1 | Pyrazine derivatives and pharmaceutical use thereof | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222159-A1 | Pyrazine derivatives and pharmaceutical use thereof | ADORA2A, HTR5A, ADORA1 | GPR139 611/4885KDM4E 3683/4885GLA 893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.